Mulpleta

On July 31, 2018, the U.S. FDA announced the approval of Shionogi’s new drug Mulpleta (lusutrombopag) to treat a specific group of adult patients with thrombocytopenia. These patients also had chronic liver disease and were scheduled to undergo surgery.

Mulpleta (lusutrombopag) Indications:

Mulpleta is a prescription medicine used to treat low platelet counts (thrombocytopenia) in adults with chronic liver disease who are planning surgery.

Mulpleta (lusutrombopag) Taking:

Mulpleta is available as 3 mg lusutrombopag tablets in a child-resistant blister pack containing 7 tablets. Take Mulpleta exactly as your healthcare provider tells you. Your healthcare provider will tell you when to start taking Mulpleta.

Before you use Mulpleta, tell your doctor about all of your medical conditions, including:

If you have any blood clots or a history of blood clots. Any blood clotting problem except thrombocytopenia.

Pregnant or planning to become pregnant. Mulpleta may harm your baby.

Breastfeeding or planning to breastfeed. It is not known if Mulpleta passes into your breast milk. Do not breastfeed during treatment with Mulpleta and for at least 28 days after the last dose. Talk with your healthcare provider about the best way to feed your baby during treatment with Mulpleta.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Mulpleta (lusutrombopag) Side Effects:

Mulpleta can cause serious side effects, including:

Thrombosis/thromboembolic complications: Mulpleta is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with blood clots and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists.

Blood clots, including in the liver, may occur in people with chronic liver disease and taking Mulpleta. If you have certain blood clotting conditions, you may be at increased risk of blood clots.

Nervous system disorders - Headache

Gastrointestinal disorders - Nausea

Skin and subcutaneous tissue disorders - Rash

Mulpleta (lusutrombopag) Storage:

Store multitube terminal devices at room temperature between 68°F and 77°F (20°C and 25°C). Mulpleta comes in child-safe blister packaging. Place the Mulpleta into the wrapper. Keep Mulpleta and all medicines away from children.